Prescott S L, Wickens K, Westcott L, Jung W, Currie H, Black P N, Stanley T V, Mitchell E A, Fitzharris P, Siebers R, Wu L, Crane J
School of Paediatrics and Child Health, University of Western Australia, Perth, Australia.
Clin Exp Allergy. 2008 Oct;38(10):1606-14. doi: 10.1111/j.1365-2222.2008.03061.x. Epub 2008 Jul 2.
This study explored the effects of maternal probiotic supplementation on immune markers in cord blood (CB) and breast milk.
CB plasma and breast milk samples were collected from a cohort of women who had received daily supplements of either 6 x 10(9) CFU/day Lactobacillus rhamnosus HN001 (n=34), 9 x 10(9) CFU/day Bifidobacterium lactis HN019 (n=35) or a placebo (n=36) beginning 2-5 weeks before delivery and continuing for 6 months in lactating women. CB plasma and breast milk (collected at 3-7 days, 3 months and 6 months postpartum) were assayed for cytokines (IL-13, IFN-gamma, IL-6, TNF-alpha, IL-10, TGF-beta1) and sCD14. Breast milk samples were also assayed for total IgA.
Neonates of mothers who received a probiotic had higher CB IFN-gamma levels (P=0.026), and a higher proportion had detectable blood IFN-gamma levels, compared with the placebo group (P=0.034), although levels were undetectable in many infants. While this pattern was evident for both probiotics, when examined separately only the L. rhamnosus HN001 group showed statistically significant higher IFN-gamma levels (P=0.030) compared with the placebo group. TGF-beta1 levels were higher in early breast milk (week 1) from the probiotic groups (P=0.028). This was evident for the B. lactis HN019 group (P=0.041) with a parallel trend in the L. rhamnosus HN001 group (P=0.075). Similar patterns were seen for breast milk IgA, which was more readily detected in breast milk from both the B. lactis HN019 (P=0.008) and the L. rhamnosus HN001 group (P=0.011). Neonatal plasma sCD14 levels were lower in the B. lactis HN019 group compared with the placebo group (P=0.041).
The findings suggest that supplementation with probiotics in pregnancy has the potential to influence fetal immune parameters as well as immunomodulatory factors in breast milk.
本研究探讨了孕期补充益生菌对脐带血（CB）和母乳中免疫标志物的影响。
从一组女性中收集CB血浆和母乳样本，这些女性在分娩前2 - 5周开始每天补充6×10⁹CFU/天的鼠李糖乳杆菌HN001（n = 34）、9×10⁹CFU/天的乳酸双歧杆菌HN019（n = 35）或安慰剂（n = 36），并在哺乳期妇女中持续补充6个月。检测CB血浆和母乳（产后3 - 7天、3个月和6个月收集）中的细胞因子（IL - 13、IFN - γ、IL - 6、TNF - α、IL - 10、TGF - β1）和sCD14。母乳样本还检测总IgA。
与安慰剂组相比，接受益生菌的母亲所生新生儿的CB IFN - γ水平更高（P = 0.026），且可检测到血液IFN - γ水平的比例更高（P = 0.034），尽管许多婴儿的水平检测不到。虽然两种益生菌都有这种趋势，但单独检查时，只有鼠李糖乳杆菌HN001组与安慰剂组相比，IFN - γ水平有统计学意义的升高（P = 0.030）。益生菌组早期母乳（第1周）中的TGF - β1水平更高（P = 0.028）。乳酸双歧杆菌HN019组明显如此（P = 0.041），鼠李糖乳杆菌HN001组有平行趋势（P = 0.075）。母乳IgA也有类似模式，在乳酸双歧杆菌HN019组（P = 0.008）和鼠李糖乳杆菌HN001组（P = 0.011）的母乳中更容易检测到。乳酸双歧杆菌HN019组新生儿血浆sCD14水平低于安慰剂组（P = 0.041）。
研究结果表明，孕期补充益生菌有可能影响胎儿免疫参数以及母乳中的免疫调节因子。
